Market News & Trends
Athira Pharma Presents Clinical & Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s & Parkinson’s Diseases
Athira Pharma, Inc. presented new clinical and preclinical data further highlighting the therapeutic potential of fosgonimeton at the AD/PD 2024 International Conference on Alzheimer’s and…
SciSparc Announces Enrollment of First Patient for its Clinical Trial for Children With Autism Spectrum Disorder
SciSparc Ltd. recently announced the first patient has been enrolled in the company's clinical trial assessing the efficacy and safety of SCI-210 for the treatment…
NodThera’s NLRP3 Inhibitor Reverses Neuroinflammation in Parkinson’s Disease Phase 1b/2a Trial
NodThera recently announced positive data from its Phase 1b/2a study in Parkinson’s disease patients, evaluating the effects of its oral, brain-penetrant NLRP3 inflammasome inhibitor NT-0796,…
Genezen Announces Strategic Process Development & Manufacturing Partnership Agreement With Seattle Children’s Research Institute
Seattle Children’s Research Institute and Genezen have unveiled a strategic manufacturing partnership for Seattle Children’s Research Institute’s X-linked agammaglobulinemia….
Hovione Partners With Dragonfly Technologies to Offer Micellar Chemistry Technology to Customers as a Sustainable Alternative to Conventional Chemical Processes
Hovione recently announced it has signed an agreement with Dragonfly Technologies, Inc. to gain access to its micellar technology for chemistry-in-water processes, developed by Prof. Bruce…
Adare Pharma Solutions to Expand Packaging & Warehousing Capabilities in Europe
Adare Pharma Solutions recently announced that work has begun to add packaging capabilities and further warehousing capacity at its….
Rentschler Biopharma Contributes to Nearly 25% of FDA-Approved Biopharmaceuticals in 2023
In 2023, the US FDA’s Center for Drug Evaluation and Research (CDER) approved 55 new drugs, 17 of which were biopharmaceuticals. Rentschler Biopharma SE, a…
Olema Oncology Announces Data Highlighting Palazestrant’s Ability to Inhibit Wild-Type & Mutant ER+ Breast Cancer Both as Monotherapy & in Combination With CDK4/6 Inhibitors
Olema Pharmaceuticals, Inc. recently announced that Molecular Cancer Therapeutics, an American Association for Cancer Research journal, has selected as a featured article a data publication that…
BiomX Enters Merger Agreement With Adaptive Phage Therapeutics & Concurrent $50-Million Financing
Acquisition will create phage therapy company with an advanced pipeline with two Phase 2 assets, BX004 for the treatment of chronic pulmonary infections in cystic fibrosis patients and BX211 for the treatment of diabetic foot osteomyelitis….
Exclusive License Agreement Secured With Erganeo for EVerGel, EVerZom's Breakthrough Treatment for Fistulas & Fibrosis of the Digestive Tract
EVerZom, a CNRS/Université Paris Cité spin-off specializing in exosomes, has announced the signature of a second exclusive license agreement with Erganeo for the development of…
Allyx Therapeutics Announces Expansion Into Parkinson’s Disease Clinical Research With Lead Compound Following IND Acceptance
Allyx Therapeutics recently announced the US FDA has accepted its Investigational New Drug Application (IND), enabling the company to proceed with clinical research in Parkinson’s…
Akari Therapeutics & Peak Bio Announce Definitive Agreement to Merge as Equals
Akari Therapeutics, Plc and Peak Bio Inc. recently announce a definitive agreement to merge as equals in an all-stock transaction. The combined entity will operate…
Elizabeth Hickman to Succeed Tim Scott as AustinPx CEO
AustinPx, developers of the next generation amorphous dispersion platform, KinetiSol Technology, and a contract development and manufacturing organization (CDMO), recently announced Elizabeth Hickman, Chief Business Officer, will succeed….
Indaptus Therapeutics Announces Positive Results From Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose Cohort
Indaptus Therapeutics, Inc. recently announced positive results from the second cohort of its Phase 1 INDP-D101 trial. Patients continue to exhibit a broad immune response…
Unicycive Therapeutics Announces Orphan Drug Designation Granted for UNI-494 for the Prevention of Delayed Graft Function in Kidney Transplant Patients
Unicycive Therapeutics, Inc. recently announced the US FDA has granted orphan drug designation (ODD) to UNI-494 for the prevention of Delayed Graft Function (DGF) in kidney….
Neurogene Announces Expansion & Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical Trial
Neurogene Inc. recently announced the expansion of its ongoing Phase 1/2 gene therapy clinical trial for NGN-401 for female pediatric patients with Rett syndrome and…
GRI Bio Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the UK
GRI Bio, Inc. recently announced the authorization of its Clinical Trial Application (CTA) by the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) to initiate…
Fortress Biotech & Cyprium Therapeutics Announce $4.1-Million Grant From NINDS to Further Develop Gene Therapy for Menkes Disease
Cyprium Therapeutics, Inc. recently announced the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH) has awarded a 3-year…
One of Northern Europe’s Largest Production Sites Successfully Taken Over by the Prange Group & Adragos Pharma
The Prange Group and its affiliate Adragos Pharma, one of Europe’s fastest growing CDMOs, has completed the acquisition transaction of Fresenius Kabi production site in…
Kinnate Biopharma Sells Investigational Pan-RAF Inhibitor to Pierre Fabre Laboratories
Kinnate Biopharma Inc. and Pierre Fabre Médicament, SAS recently announced their agreement to the sale of the company’s investigational pan-RAF inhibitor, exarafenib, and other pan-RAF…
